References
Silventoinen K, Magnusson PK, Neovius M, et al.: Does obesity modify the effect of blood pressure on the risk of cardiovascular disease? Apopulation-based cohort study of more than one million Swedish men. Circulation 2008, 118:1637–1642.
Lau DC, Douketis JD, Morrison KM, et al.; Obesity Canada Clinical Practice Guidelines Expert Panel: 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children. CMAJ 2007, 176: S1–S13.
Curtis JP, Selter JG, Wang Y, et al.: The obesity paradox: body mass index and outcomes in patients with heart failure. Arch Intern Med 2005, 165:55–61.
Yusuf S, Hawken S, Ounpuu S, et al.; INTERHEART Study Investigators: Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 2005, 366:1640–1649.
Pischon T, Boeing H, Hoffmann K et al.: General and abdominal adiposity and risk of death in Europe. N Engl J Med 2008, 359:2105–2120.
Adams TD, Gress RE, Smith SC, et al.: Long-term mortality after gastric bypass surgery. N Engl J Med 2007, 357:753–761.
Sjöström L, Narbro K, Sjöström CD, et al.; Swedish Obese Subjects Study: Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007, 357:741–752.
Knowler WC, Barrett-Connor E, Fowler SE, et al.; Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393–403.
Tuomilehto J, Lindström J, Eriksson JG, et al.; Finnish Diabetes Prevention Study Group: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001, 344:1343–1350.
Sharma AM, Golay A: Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patients with hypertension. J Hypertens 2002, 20:1873–1878.
Sharma AM, Caterson ID, Coutinho W, et al.; SCOUT Investigators: Blood pressure changes associated with sibutramine and weight management—an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT). Diabetes Obes Metab 2008 (Epub ahead of print).
Grassi G, Quarti-Trevano F, Seravalle G, et al.: Blood pressure lowering effects of rimonabant in obesity-related hypertension. J Neuroendocrinol 2008, 20(Suppl 1):63–68.
Rucker D, Padwal R, Li SK, et al.: Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007, 335:1194–1199.
Ryan DH, Espeland MA, Foster GD, et al.: Look AHEAD Research Group: Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials 2003, 24:610–628.
Torp-Pedersen C, Caterson I, Coutinho W, et al.; SCOUT Investigators: Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. Eur Heart J 2007, 28:2915–2923.
Rights and permissions
About this article
Cite this article
Sharma, A.M. Weighing in on blood pressure. Current Science Inc 11, 10–11 (2009). https://doi.org/10.1007/s11906-009-0003-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11906-009-0003-z